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Background: To assess treatment decision and outcome in patients referred for
Transcatheter Aortic Valve Implantation (TAVI) in addition to predictive factors of
mortality after TAVI.
Methods: Three-centre prospective observational study including 358 patients. End-
points were defined according to the Valve Academic Research Consortium.
Results: Of the 358 patients referred for TAVI, TAVI was performed in 235 patients
(65%), surgical aortic valve replacement (AVR) in 24 (7%) and Medical Therapy (MT)
in 99 (28%). Reasons to decline TAVI in favour of AVR/MT were patient’s preference
(29%) and peripheral vascular disease (15%; Figure 1). The logistic EuroSCORE was
significantly higher in patients who underwent TAVI and MT in comparison to those
undergoing AVR (19 vs. 10%, p0.007). At 30 days, all-cause mortality and the
combined safety endpoint was, respectively, 9 and 24% after TAVI and 8 and 25% after
AVR. All-cause mortality was significantly lower in the TAVI group compared to the MT
group at 6 months, 1 year and 2 years (12% vs. 22%, 21% vs. 33% and 31% vs. 55%,
respectively, p0.001). Multivariable analysis revealed that blood transfusion (HR: 1.19;
95% CI: 1.05-1.33), pre-existing renal failure (HR: 1.18; 95% CI: 1.06-1.33) and STS
score (HR: 1.06; 95% CI: 1.02-1.10) were independent predictors of mortality at a median
of 10 (IQR: 3-23) months after TAVI.
Conclusions: Approximately two-thirds of the patients referred for TAVI receive this
treatment with gratifying short- and long-term survival. Another 7% underwent AVR.
Prognosis is poor in patients who do not receive valve replacement therapy.
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Background: Aortic stenosis is the most common valvulopathy in industrialized
countries which is treated with trancatheter aortic valve implantation (TAVI) when
patients are inoperable or high risk. Nevertheless, female sex constitutes an unfavorable
predictive factor for the outcome of transcatheter interventions for heart diseases. In this
study we will evaluate baseline clinical characteristics, echocardiography parameters as
well as electrocardiographic changes before and after TAVI.
Methods: Consecutive patients who underwent TAVI years were evaluated from an
existed database. Baseline characteristics were collected before TAVI while echocardio-
grams and ECGs were recorded before TAVI and daily for 5 days after the procedure. We
separated patients in two groups according to gender.
Results: Overall, data from 122 patients (pts) (80.425.6 years, AVA: 0.660.14 cm2)
were analyzed. Out of them, 62 (pts) (52.5%) were female and 58 (pts) (47.5%) were
male. When we compared both groups for baseline clinical characteristics, we found that
women had smaller annulus (22.021.62 vs. 23.982.07, p0.01) and aortic valve area
(0.630.14 vs. 0.690.13, p0.012) while AVAi did not differ among two sexes
(0.370.07 vs. 0.360.08, p0.61). Women had better baseline LVEF (52.169.37 vs.
47.6913.01, p0.03) but higher systolic pressure of pneumonic artery (47.3513.96 vs.
37.9210.95, p0.01) and in higher percentage (45 pts (36.9%) vs. 25 pts (20.5%),
p0.01) comparing to men. Permanent pacemaker implantation was lower to women
comparing to men (16 pts (13.6%) vs. 29 pts(24.6%), p0.01). Furthermore, women
stayed less at coronary care unit (8.074.46 vs. 8.773.75, p0.026). There was no
significant difference for major vascular complications (11 pts(9%) vs. 10 pts (8.2%),
p1) and transfused blood units (2.34.11 vs. 2.11.7, p0.14). Similarly, in hospital
(4 pts(3.3%) vs. 1 pts (0.8%), p0.37) and 30-day mortality (5 pt (7.9%) vs. 2pt (3.6%),
p0.44) was not different.
Conclusions: In conclusion, women demonstrated better baseline clinical characteristics
except for PASP and lower need for permanent pacemaker implantation. However, they
did not differ from men as far as short term mortality is concerned.
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Background: Transcatheter Aortic Valve Implantation (TAVI) has emerged as novel
treatment option in high-risk patients with symptomatic severe aortic stenosis. The
purpose of the present study was to determine differences in gender in terms of baseline
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